Kings

You Would Love Me, If You Knew Me

Wants to meet The Rich Guys

Articles
16
Followers
18

profile/3633kings.png
Kings
What Is COVID Toe?
~3.4 mins read
The World Health Organization (WHO) has already listed the most common symptoms of COVID-19 as chills, sore throat, fever, fatigue, shortness of breath, and dry cough. Now, the doctors have added a new symptom known as the COVID toe. While it's yet to be confirmed by the WHO, the newfound unusual symptom is already dominating the headlines. All of a sudden, patients across the world are inundated with rashes on their toes which resemble chilblains. 

Doctors worldwide are overwhelmed with the number of patients reporting infected toes. They find it highly unlikely, as it usually happens during extremely cold winters. However, it’s a sign that can’t be ignored. We got in touch with Dr Swati Mohan, Dermatologist at Fortis, Faridabad to tell us all about the newfound symptom.


What is COVID toe?

Image Credit: istock
Dermatologists are trying to push COVID toe as a symptom of COVID-19 now. Dr Swati explains, “It’s a tell-tale sign of the coronavirus in which the toe colour first turns purple then blue and finally red. The discoloration of the toe looks like chilblains and is often referred to as Pseudo chilblains. It is only a clinical presentation and is now becoming an important sign of the virus, which should not be overlooked. The COVID toe usually develops several weeks after the spike of the infection has been recorded in the community i.e, several weeks after the acute phase. Besides discoloration there might also be swelling, itching and at times it could also hamper the ability to walk.”
About 20 percent of COVID-19 positive patients reportedly have this symptom and it is important to note that this usually occurs in children and young adults. 

COVID toe patients have good immunity


The good news is that patients with these lesions are doing well and seem to have good immunity, so they shouldn't panic. Dr Swati suggests, “These patients should not rush to emergency and risk exposing themselves and others to the virus. Instead, they should take rest and if there is itching, they should apply local hydrocortisone. If there is pain, then they can take Aspirin. Under such circumstances, social distancing is a must.”

Image Credit: istock
Hence the carry home message for an infected toe patient is that your body has seen the COVID virus and is creating an immune response to it. “I would like to advise that anyone with swollen toes that are purple, blue, or red should not panic. Inform your dermatologist or primary healthcare worker, if required and suggested get tested. Try to understand that it is a sign of good immunity, take rest, maintain social distancing, good hygiene, and symptomatic treatment,” concludes Dr Swati.
Lead Image Credit: istock
Anannya Chatterjee
profile/3633kings.png
Kings
People Who Recover From COVID-19 Are Still At Risk Of Having Other Complications.
~0.9 mins read
A postacute COVID-19 multisystem inflammatory syndrome (MIS) has been recognized as a rare, yet severe, complication of SARS-CoV-2 infection. First characterized in children, MIS in adults (MIS-A) has now been reported, leading to the publication of a working case definition by the Centers for Disease Control and Prevention.
The goal of this cohort study was to describe the spectrum of MIS-A presentation after SARS-CoV-2 infection. We identified cases of MIS-A among all adults with laboratory-proven subacute or convalescent SARS-CoV-2 infection at a single tertiary care medical center and described their clinical characteristics and outcomes.
Discussion
The patients with MIS-A identified in our cohort have a broader distribution of organ involvement and lower illness severity compared with those in previously published series. Most patients who met the MIS-A criteria were not identified as such by the primary clinical team. This study had some limitations. Our data likely underestimate the incidence of MIS-A because many patients with COVID-19–related admissions did not have routine comprehensive clinical and laboratory assessments to screen for this syndrome. These data suggest that, although uncommon, MIS-A has a more heterogeneous clinical presentation than previously appreciated and is commonly underdiagnosed. Future investigations, including prospective enrollments, are necessary to improve the diagnostic and treatment approaches for patients with MIS-A.

Advertisement

Loading...

Link socials

Matches

Loading...